Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2
- 31 December 1995
- journal article
- Published by Elsevier in Molecular Immunology
- Vol. 32 (17-18) , 1413-1427
- https://doi.org/10.1016/0161-5890(95)00080-1
Abstract
No abstract availableKeywords
Funding Information
- U.S. Public Health Service (CA 39841)
- National Institutes of Health
This publication has 35 references indexed in Scilit:
- Effect of VK framework‐1 glycosylation on the binding affinity of lymphoma‐specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation siteInternational Journal of Cancer, 1995
- LOW V-REGION IMMUNOGENICITY OF THERAPEUTIC DOSES OF 131I-LL2 MOUSE MONOCLONAL ANTIBODY IN LYMPHOMA PATIENTSJournal of Immunotherapy, 1994
- TREATMENT OF NON-HODGKINʼS LYMPHOMA (NHL) WITH LL2, AN ANTI-CD 22 MONOCLONAL ANTIBODYJournal of Immunotherapy, 1994
- Humanization of KC4G3, an Anti-Human Carcinoma AntibodyHybridoma, 1994
- Section Review: Humanised monoclonal antibodies for therapeutic applicationsExpert Opinion on Investigational Drugs, 1994
- The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2–6 sialyltransferase, CD75, on B cellsCell, 1991
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986
- Characterization of immunotoxins active against ovarian cancer cell lines.Journal of Clinical Investigation, 1985
- A new force field for molecular mechanical simulation of nucleic acids and proteinsJournal of the American Chemical Society, 1984
- The protein data bank: A computer-based archival file for macromolecular structuresJournal of Molecular Biology, 1977